Additional file 2 of The potential of PARP as a therapeutic target across pediatric solid malignancies
Creators: name: Keller, Kaylee M.
name: Koetsier, Joost
name: Schild, Linda
name: Amo-Addae, Vicky
name: Eising, Selma
name: van den Handel, Kim
name: Ober, Kimberley
name: Koopmans, Bianca
name: Essing, Anke
name: van den Boogaard, Marlinde L.
name: Langenberg, Karin P. S.
name: Jäger, Natalie
name: Kool, Marcel
name: Pfister, Stefan
name: Dolman, M. Emmy M.
name: Molenaar, Jan J.
name: van Hooff, Sander R.
Publisher: name: figshare
Year: 2024
Subjects: subject: Biochemistry
subject: Space Science
subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: Pharmacology
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Hematology

description: Additional file 2: Supplementary Fig. 1. Box plot of lnIC50 values for 32 different pediatric cancer cell lines following 72-hour treatment with talazoparib. Supplementary Fig. 2. A) Dose-response curves following 72-hour treatment with talazoparib in MB (red), ES (orange), OS (purple), RMS (green) and NB (blue) cell lines. All curves represent the average of two replicates and error bares indicate the standard error of the mean (SEM). B) Schematic outlining the high-throughput drug screening approach used in our study. Supplementary Fig. 3. Dose response curves of high-throughput screening combining KU- 60019 with the IC15, IC25, and IC50 of talazoparib for each cell line in A673 (orange, ES), D341 (red, MB), HOS (purple, OS), NGP (blue, NB) and RMS-YM (green, RMS). Curves are normalized to talazoparib monotherapy and represent singlicate data. Supplementary Fig. 4. Dose response curves of high-throughput screening combining SN-38 with the IC15, IC25, and IC50 of talazoparib for each cell line in A673 (orange, ES), D341 (red, MB), HOS (purple, OS), NGP (blue, NB) and RMS-YM (green, RMS). Curves are normalized to talazoparib monotherapy and represent singlicate data. Supplementary Fig. 5. Dose-response curves following 72-hour treatment with talazoparib and SN-38. All curves represent the average of two replicates and error bares indicate the standard error of the mean (SEM). Supplementary Fig. 6. Dose-response curves following 72-hour treatment with olaparib and SN-38. All curves represent the average of two replicates and error bares indicate the standard error of the mean (SEM). Supplementary Fig. 7. Dose-response curves following 72-hour treatment with pamiparib and SN-38. All curves represent the average of two replicates and error bares indicate the standard error of the mean (SEM). Supplementary Fig. 8. Dose-response curves following 72-hour treatment with talazoparib and topotecan. All curves represent the average of two replicates and error bares indicate the standard error of the mean (SEM). Supplementary Fig. 9. Dose-response curves following 72-hour treatment with olaparib and topotecan. All curves represent the average of two replicates and error bares indicate the standard error of the mean (SEM). Supplementary Fig. 10. Dose-response curves following 72-hour treatment with pamiparib and topotecan. All curves represent the average of two replicates and error bares indicate the standard error of the mean (SEM). Supplementary Fig. 11. GSEA showing biological pathways (KEGG) that are positively associated with talazoparib sensitivity in adult cell lines included in the GDSC2 dataset (adjusted p value &lt; − 0.001).